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ABSTRACT 
AIM: To assess the efficacy and safety of BioIron tablet as a herbal iron supplement for repletion in iron 
deficiency anaemic patients. 
METHODS: Thirty subjects were evaluated in 5 sessions: screening, baseline, 14th, 28th and 56th day 
accompanied with a follow up assessment at least 7 days from the last visit (day 63). The efficacy 
parameters, such as complete blood count (CBC), red blood cell indices, erythrocyte sedimentation rate 
(ESR), serum iron, total iron binding capacity and serum ferritin were evaluated. Subjects were assessed 
using SF-36 Health Questionnaire and Fatigue Severity Scale. Safety of the investigational product was 
assessed by physical examination, vital signs and adverse events. 
RESULTS: BioIron showed a significant efficacy in 56 days as evaluated by an increase in Hemoglobin (Hb) 
levels (p ≤ 0.0001) and decrease erythrocyte sedimentation rate (p ≤ 0.001). An increase in serum iron 
could be correlated to the immediate release of iron from BioIron in systemic circulation. This depicts the 
increased health status of subjects response to SF-36 Health Questionnaire (p ≤ 0.0001) and decreased 
fatigability (p ≤ 0.0001) assessed by Fatigue Severity Scale during the study course. 
CONCLUSIONS: Without any adverse events or serious adverse events, an appreciable statistical 
significance has been observed with respect to Hb level, total iron binding capacity and other laboratory 
parameters. Hence it can be reckoned that BioIron is safe and effective for the management of IDA. 
KEYWORDS: BioIron, Haemoglobin, Erythrocyte Sedimentation Rate, Ferritin, SF-36 Health Questionnaire, 
Fatigue Severity Scale. 
INTRODUCTION
 Iron deficiency anaemia (IDA) is the most 
ubiquitous nutritional deficiency worldwide, and is 
particularly prevalent in women and infants[1,2]. The 
processes of menstruation, pregnancy, and breast-feeding 
places great strains on iron stores, so that women of 
childbearing age most commonly suffer from low blood-
iron levels. It is reported that while 3% of men present 
iron deficiency, around 20% of all women, and 50% of 
pregnant women suffer from this condition. [3] 
 Low iron level is one of the most addressable 
issues in developing countries globally. Iron in the form of 
heme is vital to many metabolic functions including 
oxygen transportation in Haemoglobin. Iron is also a 
component of multiple enzymes, including cytochromes, 
necessary for energy generation and drug metabolism. 
Through the donation or acceptance of an electron, iron 
exists in either a reduced ferrous (Fe2+) or an oxidative 
ferric (Fe3+) state. The majority of functional iron is 
contained in Haemoglobin, with smaller quantities found 
in myoglobin and cytochromes. [4, 5] 
 Iron deficiency is a very common nutritional 
disorder worldwide and is known to affect approximately 
one third of the global population. While its incidence in 
affluent countries is low, the incidence of IDA in India is 
very high. [6]  
 Iron deficiency anaemia (IDA) continues to be 
major public health problem in India. Despite being the 
first country to launch the National Nutritional Anaemia 
Prophylaxis Programme in 1970, the problem of IDA in 
India remains so widespread. The economic implications 
of IDA are also massive. The issues related to control of 
IDA in India are multiple. Inadequate dietary intake of iron, 
defective iron absorption, increased iron requirements due 
to repeated pregnancies and lactation, poor iron reserves 
at birth, timing of umbilical cord clamping, timing and type 
of complementary food introduction, frequency of 
infections in children, and excessive physiological blood 
loss during adolescence and pregnancy are some of the 
causes responsible for the high prevalence of anaemia in 
India. In addition, there are other multiple programmatic 
and organizational issues. [7] 
 The first line of treatment of anaemic patients is to 
restore Haemoglobin besides controlling iron loss and to 
evaluate the actual cause. 
 A varied array of interventions exists that are 
designed to prevent and correct iron deficiency anaemia. 
These include dietary improvement, fortification of foods 
with iron, iron supplementation, and other public health 
measures, such as helminth control. All of these 
approaches improve iron status in some contexts. The 
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appropriate use of iron supplements will be an important 
part of anaemia control programs in almost all contexts. [8]  
 Physicians are often faced with the challenge in 
managing iron deficiency anaemia with oral iron when a 
patient’s iron losses exceed the maximum amount of iron 
that the gut is able to absorb. 
 Iron supplementation is generally needed to 
restore iron homeostasis and should be based on the 
degree of anaemia, underlying pathology, red blood cell 
count, serum iron panel, and erythrocyte morphology. 
These same parameters are used to monitor further iron 
supplementation needs. [9]  
 Oral iron supplements offer a more robust avenue 
for iron repletion. Frequently used forms of iron in 
supplements include ferrous and ferric iron salts, such as 
ferrous sulphate, ferrous gluconate, ferric citrate, and 
ferric sulphate[10,11]. Because of its higher solubility, 
ferrous iron in dietary supplements is more bioavailable 
than ferric iron. [11] 
 The bioavailability of iron from foods is ultimately 
determined by interactions between iron and other 
components in the digestive milieu. Several factors 
contribute to iron bioavailability such as meal 
composition, iron status, promoter substances (meat 
“factors”) and metabolic demand for iron and genetic 
inclination for iron absorption. 
 BioIron tablet contains organically bound iron 
from green gram and BioPerine®.Mung beans 
technologically enriched with iron by a soil less process 
are the source of bioavailable iron used in BioIron tablets. 
Typically, mung bean contains 100-120 ppm iron. A 
proprietary hydroponics process is used to enrich the 
beans to contain 15000-17000 ppm of bioavailable iron.  
 BioPerine® is a standardized extract from black 
pepper. It contains 95% piperine. Localized thermogenic 
action of BioPerine® on the cells results in an increase in 
the rate of absorption of supplemented nutrient 
(s).BioPerine® may be co-administered with various 
nutrients for both human and animal health. [12]  
 A bioavailability study was conducted in two 
groups of rabbits – one group receiving BioIron with 
BioPerine® and another group receiving BioIron. 
 From the results, it was evident that the animals 
from the group receiving BioIron and BioPerine® 
combination tablet showed more iron bioavailability in 
comparison to the group receiving BioIron. [12, 13]  
 Based on these observations the current study 
was planned to assess the efficacy and safety of BioIron 
tablets for Iron repletion in adult male or female patients 
suffering with Iron deficiency anaemia. 
AIMS AND OBJECTIVES 
 To evaluate the clinical efficacy of BioIron tablets in the 
management of IDA. 
 To study the adverse effects, if any, during the course of 
the treatment. 
MATERIALS AND METHODS 
PRODUCT DESCRIPTION 
 BioIron is a natural iron supplement from 
Phaseolus aureus. Mung beans are technologically enriched 
with iron by a soil less process. BioIron tablets contain 
bound iron from green gram and BioPerine®. 
ETHICS AND INFORMED CONSENT 
 This trial was conducted in accordance with the 
clinical research guidelines established by the Drugs and 
Cosmetics Act, 1940, Drugs and Cosmetics Rules, 1945. 
Ethical Guidelines for Biomedical Research on Human 
Participants, 2006 of Indian Council of Medical Research 
(ICMR) in India, the principles enunciated in the 
Declaration of Helsinki (Edinburgh, 2000) and the 
International Conference on Harmonization (ICH) 
harmonized tripartite guideline regarding Good Clinical 
Practice (GCP). Written and oral information about the 
study in a language understandable by the subjects was 
provided. Prior to entry into the study or initiation of any 
study-related procedures, the subject read, signed and 
dated the ethics committee approved informed consent 
form. This study was registered at Clinical Trials Registry 
India under the identifier CTRI/2016/03/006744 on 21 
March 2016. There were no changes to the methods or 
planned endpoints after study initiation. 
PARTICIPANTS 
 Subjects were included in the study if indicated 
“Yes” to all of the inclusion criteria and “No” to all of the 
exclusion criteria. 
Inclusion Criteria 
1) Male and Female outpatients between 18 to 55 years.  
2) Presence of iron deficiency anaemia: below normal or 
low Hb.  
3) Using effective method of contraception, if sexually 
active.  
4) Willing to come for regular follow-up visits.  
5) Able to give written informed consent.  
6) Non-use of any iron supplement for 2 weeks prior to 
enrolment to the study and to know the dosage timing 
of calcium supplement, if any.  
7) Able to comply with the requirements of the protocol. 
Exclusion Criteria 
1) Known history of hypersensitivity to herbal extracts 
or dietary supplements. 
2) Pregnant women, lactating women and women of 
child bearing potential not following adequate 
contraceptive measure, women who were found 
positive for urine pregnancy test.  
3) Medical history of current haematological disorders 
other than iron deficiency anaemia (e.g. aplastic 
anaemia, megaloblastic anaemia, sideroblastic 
anaemia, pernicious anaemia, thalassemia, sickle cell 
anaemia, etc.).  
4) Medical history of chronic renal disease. (5) Medical 
history of malabsorption syndrome, 
hemochromatosis.  
5) Obvious internal or external bleeding as documented 
by medical history.  
6) Medical history of hepatitis B, hepatitis C and/or 
exposure to HIV.  
7) Participation in another clinical trial in the last 8 
weeks before entry to Visit 0.  
8) Evidence of alcohol or drug abuse that may, in the 
opinion of the Investigator, interfere with study 
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compliance or prevents understanding of the 
objectives, investigational procedures or possible 
consequences of the study.  
9) Known or suspected hypersensitivity to iron or any of 
the components of Investigational Product.  
10) History of any recent surgeries undergone within past 
4 weeks. 
TRIAL DESIGN 
 This non-randomized, open label, clinical trial was 
conducted at Life Care Hospital, Bangalore, India. 
Compliance with study supplement was reviewed at each 
visit. This was by examination of the returned supplement. 
All accountability records were incorporated into the 
investigator’s study file. History of any medications being 
used currently were elicited and documented. The subjects 
were followed up regularly for all concomitant dosing from 
the time of baseline till the follow-up visit was captured 
and recorded. The daily food intake of the patients was 
recorded in the patient diaries provided to them at Visit 1 
(Day 0). The same was checked and verified at subsequent 
visits by the investigators. The study consisted of a 56 days 
intervention period. Subjects met with the investigational 
team during screening, Day 0, Day14, Day 28, Day 56.  
INTERVENTION 
 All enrolled subjects were asked to self-administer 
tablets (900 mg containing 8.5mg of elemental iron from 
BioIron and 2.5mg BioPerine) twice a day before food as a 
dietary supplement for a period of 56 days. 
DATA REPORTING AND MANAGEMENT 
 All data were reported in the respective hospital 
records that were then transcribed onto the Case Report 
Forms (CRFs). This info entered in the CRFs were again 
verified by the investigators a second time. It was ensured 
that the source data matches with the data entered in the 
CRFs complying with the GCP guidelines on source 
verification. Data collection during this clinical study and 
preparation for analysis were conducted by separate and 
independent functional groups. Standard procedures 
ensured all CRFs were tracked and properly routed. The 
training of all the end users and clinical data management 
associates pertaining to the database entry and validation 
process was documented. The data entry operator 
transcribed the information from the paper CRF to the 
database. Validation was conducted by the data manager. 
The database was locked post reconciliation of all data. 
The locked database was provided to the statistician who 
was independent of the study team. The inputs were then 
analyzed statistically.  
STATISTICAL ANALYSIS 
 Statistical Package for the Social Sciences (SPSS) 
software version 17.0 was used for data analysis. 
‘Wilcoxon signed rank sum test’ was used for appropriate 
data set variables to reach the best possible statistical 
conclusion. The baseline descriptors were summarized as 
means and standard deviations for continuous variables 
and as frequencies and percentages for categorical 
variables. 
RESULTS AND DISCUSSION 
 The study was initiated only after obtaining the 
approval from Life Care Hospital Institutional Ethics 
committee. The afore mentioned ethics committee was 
registered under Central Drug Standard Controlled 
Organization (CDSCO) as per the Gazette Notification 
Number F.28-10/45-H (1), dated 21 DEC 1945 and last 
amended vide notification number G.S.R. 76 (E) dated 08 
FEB 2012.  
PATIENT DISPOSITION AND CHARACTERISTICS 
 A total of thirty patients were enrolled into the 
study. There were no withdrawals or dropouts in this 
study. Treatment compliance across various visits and 
overall treatment compliance for the whole study indicates 
that 24 (80 %) patients met 100 % treatment compliance 
on visit 4 (Day 56) and on an average 76.7 % met with 100 
% treatment compliance during the whole study period. 
Demographic details of enrolled subjects were mentioned 
in Table 1. On the day of screening, the mean age of all the 
enrolled subjects was 33.7± 10.59, mean weight was 64.09 
± 14.63kgs and mean height was 153.51 ± 11.85 cm. The 
mean BMI was 26.7 ± 6.08 kg/m2 with 3 males (10%) and 
27 females (90%) enrolled into the study. While none of 
the subjects were using tobacco or alcohol. None of the 
enrolled subjects had abnormal medical history, except for 
IDA. 
EFFICACY EVALUATION 
 The laboratory parameters clearly demonstrate 
rise in Hb levels of the subjects (Figure 1). Overall results 
showed a significant increase in level of Hb for all the 
subjects when compared from screening to day 56 with 
statistical significance (p ≤ 0.0001) (Table 02).  
 There was increase in overall platelet count from 
screening to day 56, which shows almost 40% rise of 
platelet count in each subject on an average.  
 There was an increase in total leukocyte count, 
while there is a slight decrease in ESR over the visits, from 
screening through day 56. This indicates that BioIron not 
only helps increase in serum iron but also helps in 
decreasing the inflammation, if any. The serum iron 
increased from screening to final visit and the overall Iron 
Binding Capacity (IBC) showed a fall in the values from 
452.7µg/dL to 437.3µg/dL with p value 0.015 (Figure 2). 
Interestingly, there was slight rise in serum ferritin from 
screening through day 56. The serum iron increased with p 
value of 0.178 from screening to day 56, with increase in 
serum ferritin and increase in serum iron values, it could 
be interpreted that the study product BioIron could have 
released iron quickly into the systemic circulation, thereby 
increasing the bioavailability of BioIron for considerable 
period of time.  
 The Short Form (SF-36) Health Questionnaire has 
provided significant analysis of health assessment of 
subjects who participated in the study. Figure 3 depicts the 
increase in health status, while (Figure 4) shows there is a 
decreased fatigability in the participated subjects. The 
quality of life questionnaire, SF-36 Health Questionnaire 
and Fatigue Severity Scale both showed statistical 
significance (p ≤ 0.0001) which was performed by using 
“Non Parametric Wilcox on signed rank test”. This 
indicated and showed better healthy condition of the 
subjects.  
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SAFETY EVALUATION 
 During the whole course of the study it was 
observed that none of the subjects enrolled reported any 
adverse events or serious adverse events. This indicates 
the safety of the supplement. The present clinical study 
data results indicate that BioIron is safe and effective for 
the management of IDA. 
DISCUSSION: 
 After 56 days treatment with BioIron, significant 
improvement was observed in the clinical features of IDA 
with P value < 0.0001. Clinical features of IDA are mainly 
due to quantitative and qualitative reduction of Hb and 
less oxygen supply in the tissues. 1 gram haemoglobin, 
when fully saturated, combines with 1.34 mL of oxygen, 
therefore, haemoglobin concentration is an index of 
oxygen carrying capacity of blood. With the BioIron 
therapy, haemoglobin status improves, body tissues get 
adequate oxygen, body metabolism improves, and 
ultimately relief in clinical symptoms was observed. 
 The present clinical study shows the haematinic 
potential of BioIron. It is evident that the treatment of iron 
deficiency anaemia with BioIron shows statistically 
significant increase of hematologic values. Blood 
haemoglobin level was improved significantly (P<0.0001). 
A significant improvement in serum iron, total iron binding 
capacity and serum ferritin level was obtained.  
 As per the observations and results found in the 
clinical study, BioIron is an effective dietary supplement to 
manage IDA. 
CONCLUSION 
 Current clinical study shows haematinic potential 
of BioIron with significant results for the management of 
IDA. 
 Further, subjects enrolled in this study with IDA 
showed an exponential increase in Hb level when 
compared from screening to day 56 in correction of 
haematological parameters. BioIron was observed to 
directly affect the body stores of iron. Thus, for an iron 
deficient individual, this preparation is beneficial in 
replenishing iron stores of the body. Unlike the 
conventional therapy, BioIron did not impart any side 
effects thus, claiming BioIron to be safe for internal 
administration. 
 With no abnormal laboratory values, clinical 
findings or changes in vital signs and with statistical 
significance with respect to Hb and total iron binding 
capacity and other laboratory parameters, it can be 
proposed that BioIron is effective and safe for oral 
consumption in the management of IDA. 
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Table 1: Demographic Characteristics 
Parameter Statistics BioIron (N=30) 
Age (years) 
N 30 
Mean 33.7 
SD 10.59 
Median 32 
(Min, Max) (18,55) 
Weight (kg) 
N 30 
Mean 64.09 
SD 14.63 
Median 65.90 
(Min, Max) (35,88) 
Height (cm) 
N 30 
Mean 153.51 
SD 11.85 
Median 154.65 
(Min, Max) (106,170) 
Body Mass Index (kg/m2) 
N 30 
Mean 26.70 
SD 6.08 
Median 25.82 
(Min, Max) (15,38) 
Gender 
Male 3(10%) 
Female 27(90%) 
Tobacco History 
[n (%)] 
User 0 
Non User 30(100%) 
Drinking History 
[n (%)] 
Drinker 0 
Non Drinker 30(100%) 
Vegetarian /Non Vegetarian 
[n (%)] 
Vegetarian 2(6.67%) 
Non Vegetarian 28(93.33%) 
N= Total number of subjects in the group 
n= number of subjects in the given category 
SD= Standard Deviation 
(Min, Max)= (Minimum, Maximum) 
Analysis of mean change from Screening to Day 56 using non-parametric Wilcoxon signed rank test 
Parameter 
(n=30) 
Visit Median 
(IQR) 
Wilcoxon signed rank 
test P- value 
Haemoglobin (g/dL) 
Screening 11.95 (1.5) 
0.0001 Day 56 12.80 (1.5) 
Mean Change from screening to Day 56 0.50 (3.25) 
Platelet Count 
( /cu mm) 
Screening 287000 (72250) 
0.0001 Day 56 319000 (76750) 
Mean Change from screening to Day 56 23500 (30500) 
Leukocyte count 
(cells/cu mm) 
Screening 7800 (2150) 
0.0001 Day 56 9000 (1775) 
Mean Change from screening to Day 56 750 (1175) 
Erythrocyte 
Sedimentation 
Rate(mm/hr) 
Screening 22 (7) 
0.001 Day 56 18 (8) 
Mean Change from screening to Day 56 -2.50 (4) 
Serum Iron 
(μg/dL) 
Screening 59.00 (41.0) 
0.178 Day 56 53.00 (50.8) 
Mean Change from screening to Day 56 5.0 (27.50) 
Total Iron Binding 
Capacity  
(μg/dL) 
Screening 458.00 (96) 
0.015 Day 56 428.50 (75) 
Mean Change from screening to Day 56 -9.5 (29.0) 
Serum Ferritin 
(ng/mL) 
 
Screening 10.30 (37.64) 
0.082 Day 56 27.50 (38.18) 
Mean Change from screening to Day 56 3.30 (31.37) 
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Table 2: Analysis of mean change from Screening to Day 56 using non-parametric Wilcox on signed rank test 
TABLE 3: Analysis of change from screening to visit 5 for SF-36 questionnaire and Fatigue severity scale 
Parameter Visit n Mean(SD) Median(IQR) Wilcox on signed 
rank test P value 
SF-36 
questionnaire 
Change from Screening to Visit 5 
(Day -56) 
30 6.89(7.58) 2.56(8.99) 0.0001*** 
Fatigue 
severity scale 
Change from Screening to Visit 5 
(Day -56) 
30 -1.07(0.65) -1.00(0.40) 0.0001*** 
n : number of subjects in given characteristics 
SD : Standard deviation 
IQR: Inter quartile range 
FIGURES 
 
Figure 1: Mean change in Haemoglobin over the visits 
 
Parameter Visit n Median (IQR) Wilcox on signed 
rank test P- value 
Haemoglobin (g/dL) Mean Change from screening to Day 56 30 0.50 (3.25) 0.0001*** 
Platelet Count ( /cu mm) Mean Change from screening to Day 56 23500(30500) 0.0001*** 
Leukocyte count(cells/cu mm) Mean Change from screening to Day 56 750(1175) 0.0001*** 
Erythrocyte Sedimentation 
Rate (mm/hr) 
Mean Change from screening to Day 56 -2.50(4) 0.001** 
Serum Iron (μg/dL) Mean Change from screening to Day 56 5.0(27.50) 0.178 
Total Iron Binding 
Capacity(μg/dL) 
Mean Change from screening to Day 56 -9.5(29.0) 0.015* 
Serum Ferritin (ng/mL) Mean Change from screening to Day 56 3.30(31.37) 0.082 
n = number of subjects in the given category 
IQR= Inter quartile range 
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Figure 2 : Mean change in Total Iron Binding Capacity over the visits 
 
Figure 3: Mean change in SF-36 Health Questionnaire over the visits 
 
 
Figure 4: Mean change in Fatigue Severity Scale over the visits
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